Concentration of n-3 PUFA Monohydroxylated Derivatives in Adults With Obesity After n-3 PUFA Supplementation.

Phase

N/A

Condition

Diabetes Prevention

Inflammation

Obesity

Treatment

SPM Active®

Clinical Study ID

NCT06991296

24-0328

Ages 45-60
All Genders

Study Summary

The goal of this clinical trial is to learn if daily supplementation with SPM Active® can increase omega 3 polyunsaturated fatty acid derivatives and improve well-being in adults with obesity. The main questions it aims to answer are:

Does 2 g/day of SPM Active® for 12 weeks increase plasma levels of 14-hydroxydocosahexaenoic (HDHA), 17-HDHA, and 18-hydroxy eicosapentaenoic acid (HEPE)?

Does 2 g/day of SPM Active® for 12 weeks improve self-reported burnout, life satisfaction, and sleep quality?

Participants will:

Take two SPM Active® soft-gel capsules daily for 12 weeks (±2-4 days).

Provide 12-hour fasting blood samples before and after the intervention.

Complete validated surveys on burnout, life satisfaction, and sleep quality at baseline and study end.

Eligibility Criteria

Inclusion

Inclusion Criteria:

adults, ages 45-60 years
Body mass index (BMI) between 30 and 40 kg/m^2
Any race or ethnicity

Exclusion

Exclusion Criteria:

Age < 45 years or > 60 years
pregnant or breastfeeding women
BMI < 30 kg/m^2 or > 40 kg/m^2
Diagnosed type 1 or type 2 diabetes
Active autoimmune disease, liver disease, coagulopathy, or hypothyroidism
Known allergy to fish or shellfish
Current use of any of the following medications: asthma controller therapies,anticoagulants, estrogen or testosterone, daily aspirin or NSAIDs.
Inability to give informed consent
Receiving immunomodulatory or immunosuppressant therapy
Known active malignancy or undergoing treatment for malignancy
Use of n-3 PUFA supplements or high consumption of fatty fish (> 2 servings/week)within 3 months prior to enrollment.

Study Design

SPM Active®

June 02, 2025

December 31, 2026

Study Description

Purpose: This study aims to explore the effects of 'SPM Active®,' an omega-3 polyunsaturated fatty acid (n-3 PUFA) dietary supplement, on male adults with obesity. The supplement specifically targets the increase of monohydroxylated derivatives of n-3 PUFAs, which play a crucial role in reducing chronic, low-grade inflammation. The primary objective of the study is to determine whether administering SPM Active® at 2g/day for a longer duration (3 months) leads to higher levels of the monohydroxylated derivatives (14-HDHA, 17-HDHA, and 18-HEPE) in adults with obesity (BMI between 30 and 40 kg/m^2, n=33). The secondary objective is to evaluate whether administration of SPM Active® improves the following outcomes: a) burnout, b) life satisfaction, and c) sleep quality. These outcomes will be assessed using validated surveys administered before and after the intervention.

Participants: The study will include 33 healthy male and female participants of any ethnicity, aged 45-60 years, with a BMI of 30-40 kg/m^2.

Procedures: The intervention involves the administration of the dietary supplement 'SPM Active®' provided by Metagenics. All participants will take 2 soft gel capsules per day for 12 weeks, with a window of +/- 2-4 days. A 12-hour fasting blood sample will be collected from each participant before and after the intervention by a licensed phlebotomist at the UNC Nutrition Research Institute (NRI) at Kannapolis, NC. Additionally, participants will complete surveys at the start and end of the study.

Connect with a study center

UNC Nutrition Research Institute
Kannapolis, North Carolina 28081
United States
Site Not Available
UNC Nutrition Research Institute
Kannapolis 4474040, North Carolina 4482348 28081
United States
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.